> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncologic Panel to Review GSK Myeloma BLA
- URL: https://www.fdaweb.com/oncologic-panel-to-review-gsk-myeloma-bla/
- Published: 2020-06-19T12:00:00.000Z
- Updated: 2026-09-14T16:18:55.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147049

*Federal Register* notice: FDA has announced a 7/14 online/teleconferencing Oncologic Drugs Advisory Committee meeting. The panel is scheduled to discuss a GlaxoSmithKline BLA for belantamab mafodotin, indicated for treating adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-13345.pdf?ref=fdaweb.com).